heptelidic acid profile

heptelidic acid: structure given in second source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	10945834
CHEMBL ID	3585922
SCHEMBL ID	20199901
MeSH ID	M0088838

Synonym
avocettin
heptelidic acid
koningic acid
57710-57-3
6h8edv2nkq ,
CHEMBL3585922
SCHEMBL20199901
Q48791494
(+)-heptelidic acid
(5as,6r,9s,9as)-1-oxo-6-propan-2-ylspiro[3,5a,6,7,8,9a-hexahydro-2-benzoxepine-9,2'-oxirane]-4-carboxylic acid
(5as,6r,9s,9as)-1-oxo-6-(propan-2-yl)-3,5a,6,7,8,9a-hexahydro-1h-spiro[2-benzoxepine-9,2'-oxirane]-4-carboxylic acid
spiro(2-benzoxepin-9(3h),2'-oxirane)-4-carboxylic acid, 1,5a,6,7,8,9a-hexahydro-6-(1-methylethyl)-1-oxo-, (2's,5as,6r,9as)-
HY-120838
DTXSID901105608
CS-0079292

Bioassays (55)

Assay ID	Title	Year	Journal	Article
AID1231705	Inhibition of cell invasion of human A375 cells at 10 uM by Boyden chamber assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231712	Initial plasma concentration in mouse at 0.5 mg/kg, iv by tandem HPLC-mass spectrometry	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231722	Half life in mouse at 2.5 mg/kg, po by tandem HPLC-mass spectrometry	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1268214	Inhibition of D-aspartate biosynthesis in rat PC12 cells assessed as reduction of total D-aspartate level up to 0.5 uM after 24 hrs by O-phthalaldehyde/N-acetyl-L-cysteine derivatization technique-based HPLC analysis	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Identification and characterization of natural microbial products that alter the free d-aspartate content of mammalian cells.
AID1231719	Cmax in mouse at 2.5 mg/kg, po by tandem HPLC-mass spectrometry	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231691	Antiproliferative activity against human COLO205 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231728	Toxicity in Swiss mouse xenografted with human A549 cells assessed as induction of icterus at 2.5 mg/kg, ip dosed every day for 4 consecutive days during 2 weeks (q1d4 x 2 schedule)	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231695	Antiproliferative activity against human HL60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231708	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs under hypoxic conditions by MTS assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231687	Antiproliferative activity against human NAMALWA cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231733	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231693	Antiproliferative activity against human OVCAR3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231717	AUClast in mouse at 1.5 mg/kg, ip by tandem HPLC-mass spectrometry	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231718	Half life in mouse at 1.5 mg/kg, ip by tandem HPLC-mass spectrometry	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231725	Toxicity in Swiss mouse xenografted with human A549 cells assessed as induction of hepatic toxicity at 2.5 and 5 mg/kg, ip dosed every day for 5 consecutive days during 2 weeks (q1d5 x 2 schedule)	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231703	Induction of ROS generation in human PANC1 cells incubated for 1 hr by DCFH-DA dye based assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231715	Cmax in mouse at 1.5 mg/kg, ip by tandem HPLC-mass spectrometry	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231699	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231732	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231727	Toxicity in Swiss mouse xenografted with human A549 cells assessed as induction of body weight loss at 2.5 mg/kg, ip dosed every day for 4 consecutive days during 2 weeks (q1d4 x 2 schedule)	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231721	AUClast in mouse at 2.5 mg/kg, po by tandem HPLC-mass spectrometry	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231700	Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation incubated for 24 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231711	Cytotoxicity against human HT-29 cells incubated for 72 hrs under hypoxic conditions by MTS assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231694	Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231704	Antitumor activity against human A549 cells xenografted in Swiss mouse aggressive tumor model assessed as effect on rate of tumor growth at 1 mg/kg, ip dosed every day for 5 consecutive days during 2 weeks (q1d5 x 2 schedule)	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231684	Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231685	Antiproliferative activity against human SKOV3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231696	Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231726	Toxicity in Swiss mouse xenografted with human A549 cells assessed as induction of renal toxicity at 2.5 and 5 mg/kg, ip dosed every day for 5 consecutive days during 2 weeks (q1d5 x 2 schedule)	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231686	Antiproliferative activity against human KM12 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231730	Antitumor activity against human A549 cells xenografted in Swiss mouse assessed as effect on median tumor volume at 1 mg/kg, ip dosed every day for 5 consecutive days during 2 weeks (q1d5 x 2 schedule)	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1268215	Effect on L-aspartate biosynthesis in rat PC12 cells assessed as effect on total L-aspartate content up to 0.5 uM after 24 hrs by O-phthalaldehyde/N-acetyl-L-cysteine derivatization technique-based HPLC analysis	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Identification and characterization of natural microbial products that alter the free d-aspartate content of mammalian cells.
AID1231683	Antiproliferative activity against human KG1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231692	Antiproliferative activity against human TK10 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231706	Toxicity against human A375 cells assessed as reduction in cell viability at 10 uM	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231690	Antiproliferative activity against human HOP62 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231724	Toxicity in Swiss mouse xenografted with human A549 cells dosed intraperitoneally every day for 5 consecutive days during 2 weeks (q1d5 x 2 schedule)	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231713	AUClast in mouse at 0.5 mg/kg, iv by tandem HPLC-mass spectrometry	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231702	Toxicity against human A375 cells assessed as membrane integrity by measuring LDH release incubated for 24 hrs	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231689	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231720	Tmax in mouse at 2.5 mg/kg, po by tandem HPLC-mass spectrometry	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231709	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs under normoxic conditions by MTS assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231716	Tmax in mouse at 1.5 mg/kg, ip by tandem HPLC-mass spectrometry	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231710	Cytotoxicity against human HT-29 cells incubated for 72 hrs under normoxic conditions by MTS assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231698	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231714	Half life in mouse at 0.5 mg/kg, iv by tandem HPLC-mass spectrometry	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1268209	Effect on L-aspartate biosynthesis in rat PC12 cells assessed as effect on intracellular L-aspartate content up to 0.5 uM after 24 hrs by O-phthalaldehyde/N-acetyl-L-cysteine derivatization technique-based HPLC analysis	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Identification and characterization of natural microbial products that alter the free d-aspartate content of mammalian cells.
AID1231729	Antitumor activity against human A549 cells xenografted in Swiss mouse assessed as reduction of subcutaneous tumor growth at 1 mg/kg, ip dosed every day for 5 consecutive days during 2 weeks (q1d5 x 2 schedule)	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231701	Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation incubated for 24 hrs by conventional ATP quantification method relative to untreated control	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231731	Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1268204	Increase in intracellular D-aspartate content in HEK293 cells at 5 ug after 24 hrs by O-phthalaldehyde/N-acetyl-L-cysteine derivatization technique-based HPLC analysis relative to total aspartate (Rvb = 7.38 +/- 1.9%)	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Identification and characterization of natural microbial products that alter the free d-aspartate content of mammalian cells.
AID1231723	Oral bioavailability in mouse at 2.5 mg/kg by tandem HPLC-mass spectrometry	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1268208	Inhibition of D-aspartate biosynthesis in rat PC12 cells assessed as reduction of intracellular D-aspartate content up to 0.5 uM after 24 hrs by O-phthalaldehyde/N-acetyl-L-cysteine derivatization technique-based HPLC analysis	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Identification and characterization of natural microbial products that alter the free d-aspartate content of mammalian cells.
AID1231688	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
AID1231697	Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anticancer activity of koningic acid and semisynthetic derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (11.76)	18.7374
1990's	8 (23.53)	18.2507
2000's	6 (17.65)	29.6817
2010's	8 (23.53)	24.3611
2020's	8 (23.53)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	34 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
adenine [no description available]	2.1	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.17	1	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
itaconic acid itaconic acid : A dicarboxylic acid that is methacrylic acid in which one of the methyl hydrogens is substituted by a carboxylic acid group.	2.21	1	dicarboxylic acid; dicarboxylic fatty acid; olefinic compound	fungal metabolite; human metabolite
pyruvaldehyde Pyruvaldehyde: An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals.. methylglyoxal : A 2-oxo aldehyde derived from propanal.	2.01	1	2-oxo aldehyde; propanals	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
3-aminobenzamide [no description available]	2.01	1	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
thymidine [no description available]	1.96	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	2.13	1	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	1.96	1	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
dithionitrobenzoic acid Dithionitrobenzoic Acid: A standard reagent for the determination of reactive sulfhydryl groups by absorbance measurements. It is used primarily for the determination of sulfhydryl and disulfide groups in proteins. The color produced is due to the formation of a thio anion, 3-carboxyl-4-nitrothiophenolate.. dithionitrobenzoic acid : An organic disulfide that results from the formal oxidative dimerisation of 2-nitro-5-thiobenzoic acid. An indicator used to quantify the number or concentration of thiol groups.	1.97	1	nitrobenzoic acid; organic disulfide	indicator
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.1	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	7.05	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	1.99	1	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	2.54	2
glyceraldehyde 3-phosphate Glyceraldehyde 3-Phosphate: An aldotriose which is an important intermediate in glycolysis and in tryptophan biosynthesis.. glyceraldehyde 3-phosphate : An aldotriose phosphate that is the 3-phospho derivative of glyceraldehyde. It is an important metabolic intermediate in several central metabolic pathways in all organisms.	1.96	1	glyceraldehyde 3-phosphate	mouse metabolite
sesquiterpenes [no description available]	4.89	34
geldanamycin [no description available]	2.13	1	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound	antimicrobial agent; antineoplastic agent; antiviral agent; cysteine protease inhibitor; Hsp90 inhibitor
geldanamycin [no description available]	2.13	1
bleomycin [no description available]	2.11	1	bleomycin	antineoplastic agent; metabolite
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.21	1	cysteinium	fundamental metabolite
monorden monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II	2.4	2	cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols	antifungal agent; metabolite; tyrosine kinase inhibitor
nad NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.	2.02	1	organophosphate oxoanion	cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite
heme Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.	6.99	1
apyrase Apyrase: A calcium-activated enzyme that catalyzes the hydrolysis of ATP to yield AMP and orthophosphate. It can also act on ADP and other nucleoside triphosphates and diphosphates. EC 3.6.1.5.	2.03	1
plicamycin mithramycin A: structure given in first source	2.13	1
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	1.98	1	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
3-methyladenine N3-methyladenine: structure in first source	2.1	1

Condition	Relationship Strength	Studies
Cancer of Lung [description not available]	2.11	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.11	1
Malignant Melanoma [description not available]	2.41	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	7.41	1
Innate Inflammatory Response [description not available]	2.21	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.21	1
Endotoxemia A condition characterized by the presence of ENDOTOXINS in the blood. On lysis, the outer cell wall of gram-negative bacteria enters the systemic circulation and initiates a pathophysiologic cascade of pro-inflammatory mediators.	2.21	1
Cancer of Pancreas [description not available]	2.31	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.31	1
Cancer of the Thyroid [description not available]	2.41	1
Thyroid Neoplasms Tumors or cancer of the THYROID GLAND.	2.41	1
Benign Neoplasms [description not available]	2.48	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.48	2
Cancer of Cervix [description not available]	2.1	1
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2.1	1
Degenerative Diseases, Central Nervous System [description not available]	2.05	1
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	2.05	1
Autoimmune Diabetes [description not available]	2.01	1
Diabetes Mellitus, Adult-Onset [description not available]	2.01	1
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	2.01	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.01	1
Pheochromocytoma, Extra-Adrenal [description not available]	2.01	1
Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)	2.01	1
Glial Cell Tumors [description not available]	1.99	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	1.99	1
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	1.99	1
Experimental Neoplasms [description not available]	1.96	1

heptelidic acid

Description

Cross-References

Synonyms (15)

Bioassays (55)

Research

Studies (34)

Study Types

heptelidic acid

Description

Cross-References

Synonyms (15)

Bioassays (55)

Research

Studies (34)

Study Types

Related Drugs (26)

Related Conditions (27)